Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kim Horrigan
Institution:
Foghorn Therapeutics (United States)
Observed institution:
Foghorn Therapeutics (United States)
ORCID:
0009-0009-9724-6499
Observed ORCID:
0009-0009-9724-6499
OpenAlex ID:
A5001848151
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
2024
·
J. Andrew Livingston
, Jean-Yves Blay
, et al.
·
Clinical Cancer Research
·
50
Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies
2023
·
Courtney D. DiNardo
, Michael R. Savona
, et al.
·
Blood
·
23
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
·
Clinical Cancer Research
·
19
The identification and characterization of a STAT5 gene signature in hematologic malignancies
2015
·
Dmitriy Sonkin
, Michael Palmer
, et al.
·
Cancer Biomarkers
·
12
PDF
Abstract A013: Leukemic stem cell differentiation visible at single-cell resolution in AML patients treated with BRG1/BRM inhibitor FHD-286
2023
·
GiNell Elliott
, Jessica Wan
, et al.
·
Molecular Cancer Therapeutics
·
1
Abstract C016: Evaluating clinical biomarkers of FHD-286, a potent and selective inhibitor of BRG1/BRM, in metastatic uveal melanoma
2023
·
Jessica Wan
, Kim Horrigan
, et al.
·
Molecular Cancer Therapeutics
·
1
Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignancies
2026
·
Michael P. Collins
, David L. Lahr
, et al.
·
medRxiv
PDF
Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
2025
·
Mike Collins
, David Lahr
, et al.
·
Blood
Machine learning-powered integration of global proteomics and ex vivo sensitivity unveils a protein signature predictive of treatment success to AML therapy: Validation in patients treated with FHD-286, a SMARCA2/4 dual inhibitor
2025
·
James Sorrentino
, Salvador Martinez-Bartolome
, et al.
·
Blood
PDF
Supplementary Figure 13 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 15 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Data 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 12 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 11 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Figure 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
PDF
Supplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
Supplementary Table 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025
·
Courtney D. DiNardo
, Amir T. Fathi
, et al.
Show more works
View as search
Works count:
59
Citation count:
106
H-index:
4
I10-index:
4
Year
Topic
Type